Related references
Note: Only part of the references are listed.Sex Differences in Lopinavir and Ritonavir Pharmacokinetics Among HIV-Infected Women and Men
Obi C. Umeh et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Hepatotoxicity and Gastrointestinal Intolerance When Healthy Volunteers Taking Rifampin Add Twice-Daily Atazanavir and Ritonavir
David W. Haas et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets
Hanneke M. J. Nijland et al.
AIDS (2008)
Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis
Yuan Ren et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis
Esteban Ribera et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children
J Ananworanich et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2005)
Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers
CJL la Porte et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: Is it different than in HIV-uninfected persons?
FM Gordin et al.
CLINICAL INFECTIOUS DISEASES (2004)
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4
SF Zhou et al.
CURRENT DRUG METABOLISM (2004)
Medical progress: Drug-induced hepatotoxicity
WM Lee
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Pharmacokinetic interactions with rifampicin - Clinical relevance
M Niemi et al.
CLINICAL PHARMACOKINETICS (2003)
Diurnal variation of plasma protease inhibitor concentrations
US Justesen et al.
AIDS (2002)
Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: A multicenter clinical trial
RM Jasmer et al.
ANNALS OF INTERNAL MEDICINE (2002)
Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: Potent inhibition of CYP2C19 and CYP3A
Z Desta et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Share Paper
